BCRX 240517 4.00C (BCRX240517C4000) Stock Options, News & Quotes

US OptionsDetailed Quotes

BCRX240517C4000

Watchlist

1.45
-0.10-6.45%

15min DelayClose May 13 16:00 ET

1.45High1.42Low

Intraday

News

BioCryst Says Orladeyo Granted Approval in Mexico
BioCryst Pharmaceuticals (BCRX) said Monday that it has received approval for Orladeyo from Mexico's Federal Commission for Protection against Health Risks for the prophylaxis of hereditary angioedema
MT NewswiresMay 13 10:31 ET
Express News | Orladeyo® (Berotralstat) Approved in Mexico
ReutersMay 13 07:08 ET
ORLADEYO (Berotralstat) Approved in Mexico
RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has
GlobeNewswireMay 13 07:00 ET
Here's What Analysts Are Forecasting For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its First-Quarter Results
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) just released its quarterly report and things are looking bullish. Revenues beat expectations coming in atUS$93m, ahead of estimates by 8.5%. Statutor
Simply Wall StMay 10 08:47 ET
Express News | BioCryst Presents New Real-world Evidence Showing Significant Reductions In Healthcare Resource Utilization Among Patients With Hereditary Angioedema Following Initiation Of Orladeyo (Berotralstat)
BenzingaMay 9 07:41 ET
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients With HAE Following Initiation of ORLADEYO (Berotralstat)
RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO (berotralstat)
GlobeNewswireMay 9 07:00 ET

Comments

Trytosaveabit

May 9 19:43

Update

$BioCryst Pharmaceuticals(BCRX.US)$ Benzinga· 1 min BioCryst Presents New Real-world Evidence Showing Significant Reductions In Healthcare Resource Utilization Among Patients With Hereditary Angioedema Following Initiation Of Orladeyo (Berotralstat

Trytosaveabit

May 6 19:14

Not bad

$BioCryst Pharmaceuticals(BCRX.US)$ BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million—
—Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) —
—Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials—

Jaguar8

Apr 17 16:32

$BioCryst Pharmaceuticals(BCRX.US)$
NEWS
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

Trytosaveabit

Apr 10 19:14

Don’t put much into analyst’s targets, but!

$BioCryst Pharmaceuticals(BCRX.US)$ Still with the buy rating with a 12 PT!

Stock Region

Feb 24 07:01

American Biotech Company Presents Data That Treats Hereditary Angioedema

Unprecedented HAE Attack Rate Reductions with ORLADEYO® (berotralstat): A Breakthrough in Medical Science.
BioCryst Pharmaceuticals, Inc., a leading American biotechnology company, has presented new real-world data that shows significant and sustained reductions in hereditary angioedema (HAE) attack rates after patients began treatment with ORLADEYO® (berotralstat). This groundbreaking development could have far-reaching imp...